BioAtla, Inc.

Item 5. Other Information.

During the three months ended June 30, 2026, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

First Amendment to EXUMA License Agreement

On August 12, 2026 (the “Effective Date”), we entered into the First Amendment (the “First Amendment”) to the Amended and Restated Exclusive License Agreement, dated November 22, 2019 (the “EXUMA License Agreement”), with EXUMA Biotech Corp. (formerly F1 Oncology, Inc.), a Delaware corporation (“EXUMA”), covering certain CAR-T therapies. Under the terms of the First Amendment, and in full consideration for the license and other rights granted by the Company under the EXUMA License Agreement, EXUMA has agreed to pay us $250,000 in immediately available funds within two (2) business days of the Effective Date (the “Amendment Pay-Off Amount”). The Amendment Pay-Off Amount satisfies in full any and all royalty payment obligations contemplated by the EXUMA License Agreement. Under the terms of the First Amendment, the exclusive license granted to EXUMA under the EXUMA License Agreement is amended to be royalty-free, fully paid-up, irrevocable, perpetual and non-terminable, and EXUMA shall be responsible for all Joint Patent (as defined in the EXUMA License Agreement) costs, whether currently outstanding or due in the future.

The above description of the First Amendment is qualified in its entirety by reference to the full text of the First Amendment, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.